
Hans-joachim, Schmoll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1775339/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology, 2012, 23, 2479-2516.	0.6	1,233
2	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 2004, 22, 1209-1214.	0.8	1,007
3	Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. Journal of Clinical Oncology, 2011, 29, 1465-1471.	0.8	669
4	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. European Urology, 2008, 53, 478-496.	0.9	488
5	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1225-1233.	5.1	484
6	A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 1-10.	1.0	391
7	Cyclooxygenase-2: a novel target for cancer chemotherapy?. Journal of Cancer Research and Clinical Oncology, 2001, 127, 411-417.	1.2	381
8	Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer. Journal of Clinical Oncology, 2003, 21, 3098-3104.	0.8	277
9	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163.	0.3	275
10	Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group. Journal of Clinical Oncology, 2001, 19, 2647-2657.	0.8	264
11	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. Journal of Clinical Oncology, 2007, 25, 4217-4223.	0.8	258
12	Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. Journal of Clinical Oncology, 2007, 26, 102-109.	0.8	243
13	European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. European Urology, 2008, 53, 497-513.	0.9	243
14	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 1355-1369.	5.1	228
15	Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines. Journal of Clinical Oncology, 2008, 26, 2118-2123.	0.8	226
16	German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbeck's Archives of Surgery, 2013, 398, 347-375.	0.8	226
17	Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Journal of Clinical Oncology, 2015, 33, 3733-3740.	0.8	217
18	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Supportive Care in Cancer, 2010, 18, 423-431.	1.0	215

#	Article	IF	CITATIONS
19	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). Journal of Clinical Oncology, 2012, 30, 3588-3595.	0.8	194
20	Integrating Oxaliplatin into the Management of Colorectal Cancer. Oncologist, 2001, 6, 24-28.	1.9	165
21	Has the new TNM classification for colorectal cancer improved care?. Nature Reviews Clinical Oncology, 2012, 9, 119-123.	12.5	163
22	Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations. Oncologist, 2007, 12, 1143-1150.	1.9	162
23	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. Oncology, 2005, 68, 3-11.	0.9	156
24	Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. Journal of Clinical Oncology, 2008, 26, 5910-5917.	0.8	149
25	Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncology, The, 2014, 15, 1481-1492.	5.1	139
26	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2020, 38, 3314-3324.	0.8	139
27	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. Journal of Clinical Oncology, 2016, 34, 843-853.	0.8	128
28	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	0.8	116
29	Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. European Journal of Cancer, 2005, 41, 199-205.	1.3	115
30	Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety. Oncologist, 2015, 20, 450-458.	1.9	103
31	Cisplatin resistance and oncogenes - a review. Anti-Cancer Drugs, 2000, 11, 225-236.	0.7	102
32	Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Research, 2003, 63, 513-21.	0.4	95
33	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 2018, 110, 638-648.	3.0	90
34	Presence of Mesenchymal Stem Cells in Human Bone Marrow After Exposure to Chemotherapy: Evidence of Resistance to Apoptosis Induction. Stem Cells, 2006, 24, 2753-2765.	1.4	88
35	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	0.8	87
36	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1615-1624.	1.2	84

#	Article	IF	CITATIONS
37	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
38	Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: Report of five cases. Arthritis and Rheumatism, 2011, 63, 2540-2542.	6.7	79
39	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	1.3	73
40	Sequelae of Treatment in Long-term Survivors of Testis Cancer. European Urology, 2011, 60, 516-526.	0.9	70
41	Metastases to the Breast from Non-mammary Malignancies. Academic Radiology, 2011, 18, 565-574.	1.3	67
42	MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Critical Reviews in Oncology/Hematology, 2015, 94, 31-44.	2.0	66
43	Growth inhibition of colorectal carcinoma by lentiviral <i>TRAIL</i> â€ŧransgenic human mesenchymal stem cells requires their substantial intratumoral presence. Journal of Cellular and Molecular Medicine, 2010, 14, 2292-2304.	1.6	65
44	Bortezomib Inhibits Cell-Cell Adhesion and Cell Migration and Enhances Epidermal Growth Factor Receptor Inhibitor–Induced Cell Death in Squamous Cell Cancer. Cancer Research, 2007, 67, 727-734.	0.4	64
45	Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Journal of Clinical Oncology, 2021, 39, 17-29.	0.8	58
46	New chemotherapy approaches in colorectal cancer. Current Opinion in Oncology, 2001, 13, 275-286.	1.1	57
47	Interdisciplinary Consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence–Based Medicine (EBM). European Urology, 2001, 40, 372-391.	0.9	56
48	Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. European Journal of Haematology, 2005, 74, 263-266.	1.1	56
49	Loss of Oct-3/4 Expression in Embryonal Carcinoma Cells Is Associated with Induction of Cisplatin Resistance. Tumor Biology, 2006, 27, 71-83.	0.8	55
50	The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. Cell Cycle, 2009, 8, 916-924.	1.3	54
51	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer, 2016, 16, 699.	1.1	54
52	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis Journal of Clinical Oncology, 2014, 32, 3501-3501.	0.8	51
53	Towards improved drugs, combinations and patient selection. Nature Reviews Clinical Oncology, 2014, 11, 79-80.	12.5	49
54	Cholic acid–carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. Journal of Inorganic Biochemistry, 2003, 94, 335-342.	1.5	47

#	Article	IF	CITATIONS
55	Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. European Journal of Cancer, 2009, 45, 1184-1187.	1.3	45
56	Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. Journal of Cancer Research and Clinical Oncology, 2004, 130, 388-94.	1.2	44
57	Improving outcomes in colorectal cancer: Where do we go from here?. European Journal of Cancer, 2013, 49, 2476-2485.	1.3	43
58	Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. Acta Radiologica, 2014, 55, 45-53.	0.5	43
59	The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. Oncologist, 2001, 6, 3-11.	1.9	40
60	Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III. Clinical Colorectal Cancer, 2009, 8, 59-60.	1.0	40
61	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6ÂMonths of Completing Adjuvant Oxaliplatin-Based Therapy. Targeted Oncology, 2016, 11, 383-400.	1.7	40
62	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	1.3	40
63	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial Journal of Clinical Oncology, 2013, 31, 3531-3531.	0.8	39
64	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	0.8	37
65	Update on Capecitabine in Colorectal Cancer. Oncologist, 2006, 11, 1003-1009.	1.9	34
66	Crizotinib in refractory <scp>ALK</scp> â€positive diffuse large <scp>B</scp> â€cell lymphoma: a case report with a shortâ€term response. European Journal of Haematology, 2014, 92, 268-270.	1.1	34
67	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet, The, 2007, 370, 105-107.	6.3	33
68	Introduction. Oncology, 2005, 69, 1-3.	0.9	31
69	When Wishful Thinking Leads to a Misty-Eyed Appraisal: The Story of the Adjuvant Colon Cancer Trials With Edrecolomab. Journal of Clinical Oncology, 2009, 27, 1926-1929.	0.8	30
70	Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochemistry and Cell Biology, 2010, 134, 197-204.	0.8	30
71	MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1197-1204.	1.2	30
72	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Present and Future Role in Gastrointestinal Cancer Treatment: A Review. Oncologist, 2006, 11, 602-611.	1.9	29

#	Article	IF	CITATIONS
73	Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Supportive Care in Cancer, 2009, 17, 1543-1552.	1.0	29
74	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45.	1.3	29
75	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 60-64.	1.0	28
76	Biomolecules Linked to Transition Metal Complexes - New Chances for Chemotherapy. Current Medicinal Chemistry, 2003, 10, 2033-2044.	1.2	27
77	Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colorectal Cancer, 2004, 4, 46-50.	1.0	27
78	2-(4-(tetrahydro-2 <i>H</i> -pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): A Novel Platinum Compound that Overcomes Cisplatin Resistance and Induces Apoptosis by Mechanisms Different from that of Cisplatin. Journal of Medicinal Chemistry, 2008, 51, 5413-5422.	2.9	25
79	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	3.0	25
80	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6 Journal of Clinical Oncology, 2018, 36, 3500-3500.	0.8	25
81	Threshold Change in CEA as a Predictor ofÂNon-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. Journal of the National Cancer Institute, 2020, 112, 1127-1136.	3.0	24
82	Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer, 2012, 12, 356.	1.1	23
83	Adjuvant Therapy for Early Colon Cancer. Drugs, 2011, 71, 2257-2275.	4.9	21
84	Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β1â€integrinâ€dependent mechanism. International Journal of Cancer, 2016, 138, 964-975.	2.3	20
85	Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS ONE, 2017, 12, e0178930.	1.1	18
86	Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Molecules, 2019, 24, 2865.	1.7	18
87	Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. JAMA Oncology, 2021, 7, 255.	3.4	17
88	Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207) Journal of Clinical Oncology, 2014, 32, 3503-3503.	0.8	17
89	Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. Oncology, 2015, 89, 137-142.	0.9	16
90	What is the role of lymph node metastases in the progression of colorectal cancer?. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 633-634.	8.2	16

#	Article	IF	CITATIONS
91	Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study. Acta Oncológica, 2014, 53, 392-398.	0.8	15
92	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer, 2020, 130, 63-71.	1.3	15
93	Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1446-1453.	1.2	14
94	Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Therapeutic Advances in Medical Oncology, 2010, 2, 161-174.	1.4	14
95	A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. Annals of Oncology, 2017, 28, 922-930.	0.6	14
96	"CHARTA― FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO Journal of Clinical Oncology, 2017, 35, 3533-3533.	0.8	14
97	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. Blood. 2016. 128. 511-511.	0.6	13
98	A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. Journal of Cancer Research and Clinical Oncology, 2001, 127, 96-100.	1.2	12
99	Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, 257-262.	1.0	11
100	Inflammatory Lesions of the Peritoneum Mimic Carcinomatosis After Treatment With Intravenous Chemotherapy and Intraperitoneal Catumaxomab. Journal of Clinical Oncology, 2011, 29, e644-e646.	0.8	11
101	FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer?. The Lancet Gastroenterology and Hepatology, 2018, 3, 143-145.	3.7	11
102	Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer. JAMA Network Open, 2020, 3, e2020425.	2.8	11
103	Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. PLoS ONE, 2017, 12, e0169921.	1.1	11
104	Manic episode in an ifosfamide-treated patient. General Hospital Psychiatry, 2000, 22, 52-53.	1.2	10
105	The Future Development of Bevacizumab in Colorectal Cancer. Oncology, 2005, 69, 34-45.	0.9	10
106	Systemic treatment of liver metastases from colorectal cancer. Therapeutic Advances in Medical Oncology, 2013, 5, 193-203.	1.4	9
107	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	0.5	9
108	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. Oncologist, 2021, 26, 302-309.	1.9	9

#	Article	IF	CITATIONS
109	Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA) Journal of Clinical Oncology, 2012, 30, 388-388.	0.8	9
110	Human Chorionic Gonadotropin-Induced Hyperthyroidism in Germ Cell Cancer – a Case Presentation and Review of the Literature. Oncology Research and Treatment, 2007, 30, 330-334.	0.8	7
111	Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein–Barr virus DNAemia. Leukemia and Lymphoma, 2013, 54, 133-137.	0.6	7
112	Advanced Seminoma and Nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, 2011, 78, S456-S468.	0.5	6
113	Trans-sectoral care in patients with colorectal cancer: Protocol ofÂthe randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer, 2015, 15, 997.	1.1	6
114	<scp>MRI</scp> rectal cancer in Australia and New Zealand: An audit from the <scp>PETACC</scp> â€6 trial. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 607-615.	0.9	6
115	Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2019, 2, e1911750.	2.8	6
116	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database Journal of Clinical Oncology, 2017, 35, 3535-3535.	0.8	6
117	Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines. Journal of Cancer Research and Clinical Oncology, 1998, 124, 435-443.	1.2	5
118	Benefits and Risks of Colorectal Cancer Screening. Oncology Research and Treatment, 2014, 37, 11-20.	0.8	5
119	Targeting HER2: precision oncology for colorectal cancer. Lancet Oncology, The, 2016, 17, 685-686.	5.1	5
120	Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. Clinical Colorectal Cancer, 2021, 20, 130-136.	1.0	5
121	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 2022, 114, 60-67.	3.0	5
122	Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival Journal of Clinical Oncology, 2015, 33, 680-680.	0.8	5
123	CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209) Journal of Clinical Oncology, 2017, 35, 658-658.	0.8	5
124	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database Journal of Clinical Oncology, 2019, 37, 3502-3502.	0.8	5
125	To the Editor. Journal of Clinical Oncology, 2008, 26, 2226-2227.	0.8	4
126	Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Response to the Local Treatment After Chemoradiation and Surgery as Secondary Endpoint. Annals of Oncology, 2013, 24, iv120.	0.6	4

HANS-JOACHIM, SCHMOLL

#	Article	IF	CITATIONS
127	Dalotuzumab in chemorefractory <i>KRAS</i> exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. International Journal of Cancer, 2017, 140, 431-439.	2.3	4
128	Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anti-Cancer Drugs, 1999, 10, 545-550.	0.7	3
129	Protective effect of oral phosphatidylcholine on radiation-induced release of intestinal peptidases in rats. Journal of Cancer Research and Clinical Oncology, 2001, 127, 444-448.	1.2	3
130	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	1.4	3
131	Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO Journal of Clinical Oncology, 2016, 34, 11004-11004.	0.8	3
132	Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer Journal of Clinical Oncology, 2018, 36, 3525-3525.	0.8	3
133	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
134	Chemotherapy in rectal cancer. European Journal of Cancer, Supplement, 2005, 3, 389-400.	2.2	2
135	CAIRO and FOCUS – Authors' reply. Lancet, The, 2007, 370, 1905.	6.3	2
136	Reply to O. Gires et al. Journal of Clinical Oncology, 2010, 28, e241-e242.	0.8	2
137	Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. Mycoses, 2013, 56, 90-92.	1.8	2
138	Reply to P. Potemski and K. Bujko. Journal of Clinical Oncology, 2021, 39, 1306-1308.	0.8	2
139	IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma Journal of Clinical Oncology, 2012, 30, 633-633.	0.8	2
140	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts Journal of Clinical Oncology, 2014, 32, 3538-3538.	0.8	2
141	Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial Journal of Clinical Oncology, 2017, 35, 3544-3544.	0.8	2
142	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database Journal of Clinical Oncology, 2018, 36, 612-612.	0.8	2
143	A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703 Journal of Clinical Oncology, 2015, 33, 3049-3049.	0.8	2
144	The future of colorectal cancer research: an interview with Hans Schmoll. Future Oncology, 2020, 16, 2269-2271.	1.1	2

#	Article	IF	CITATIONS
145	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. Journal of the National Cancer Institute, 2022, 114, 819-828.	3.0	2
146	S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?. Lancet Oncology, The, 2010, 11, 808-809.	5.1	1
147	Do we need oncology trials tailored for the elderly or frail?. Lancet, The, 2011, 377, 1725-1727.	6.3	1
148	Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP) Journal of Clinical Oncology, 2014, 32, 3601-3601.	0.8	1
149	Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin Journal of Clinical Oncology, 2015, 33, 3593-3593.	0.8	1
150	Crizotinib in ALK-Positive Diffuse Large B-Cell Lymphoma: A Case Report. Blood, 2012, 120, 4862-4862.	0.6	1
151	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database Journal of Clinical Oncology, 2015, 33, 666-666.	0.8	1
152	Detection of an Occult B-cell Lymphoma in the Donor's Bone Marrow Prior to HLA-Matched Sibling Transplantation. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 169-170.	1.8	0
153	Perspectives for Onkologie. Onkologie, 2011, 34, 659-659.	1.1	0
154	Administration of Chemotherapy by an Arteriovenous Fistula in a Patient with Metastatic Rectal Cancer after Life-Threatening, Port Thrombosis-Associated Cava Superior Syndrome. Onkologie, 2012, 35, 440-442.	1.1	0
155	What Is the Ongoing Recommendation in the Management of Rectal Cancer?. , 2012, , 9-18.		0
156	Optimum Duration of Metastatic Colorectal Cancer Treatment. Current Colorectal Cancer Reports, 2013, 9, 223-229.	1.0	0
157	Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours?. Lancet Oncology, The, 2017, 18, 1138-1139.	5.1	0
158	What Is the Ongoing Recommendation in the Management of Rectal Cancer?. , 2018, , 59-67.		0
159	Are Capecitabine and 5FU Equivalent When Combined with Radiotherapy?. , 2018, , 259-262.		0
160	422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs). Annals of Oncology, 2020, 31, S420-S421.	0.6	0
161	Long-term use of sustained-release cytarabine for symptomatic management and treatment of meningeosis neoplastica Journal of Clinical Oncology, 2012, 30, e19579-e19579.	0.8	Ο
162	A phase II-III clinical study with the immunomodulator MGN1703 in patientsÂwith advanced colorectal carcinoma:ÂThe IMPACT study Journal of Clinical Oncology, 2012, 30, e14152-e14152.	0.8	0

#	Article	IF	CITATIONS
163	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database Journal of Clinical Oncology, 2014, 32, 3537-3537.	0.8	0
164	IMPACT trial: Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma Journal of Clinical Oncology, 2014, 32, 3615-3615.	0.8	0
165	Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database Journal of Clinical Oncology, 2015, 33, 6580-6580.	0.8	0
166	Abstract B61: Exploratory analyses of the randomized phase 2 IMPACT study: Patients with response to prior induction chemotherapy have improved outcome when treated with the TLR-9 agonist MGN1703. , 2015, , .		0
167	Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab Journal of Clinical Oncology, 2016, 34, 3551-3551.	0.8	0
168	Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database Journal of Clinical Oncology, 2016, 34, 3620-3620.	0.8	0
169	Phase II-study of sequential high-dose-chemotherapy with paclitaxel, ifosfamide, carboplatin, etoposide(P-ICE) in patients with relapsed or refractory germ cell tumors (GCT) Journal of Clinical Oncology, 2017, 35, 4552-4552.	0.8	0